The 3-D printing market for medical device applications is anticipated to grow 15.4 percent from 2013 to 2019, according to a Transparency Market Research report. In 2012, the market was valued at $354.4 million and is expected to reach $965.5 million in six years.
The latest iteration of the Bipartisan Budget Act of 2013 includes language that would strike down the 2.3% medical-device tax. The measure, which cleared the House last week, has been approved in the Senate and heads to President Barak Obama for his signature.
In a surprising development that has revived intense speculation over the fate of Amarin, the FDA has delayed any decision about whether to widen an indication for the Vascepa prescription fish oil pill. The move was expected in December 2013 and the delay has now triggered intrigue over what appears to be a complex minuet between the agency and the ‘little drugmaker that could.’
The FDA announced in December 2013 that it is recommending the bedtime dose of Zolpidem (brand name Ambien) be lowered due to the risk of next-morning impairment. In a press release issued in December 2013, the FDA says it recommending the change “because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving.” The FDA is requiring manufacturers of Ambien, Ambien CR, Edluar and Zolpimist to lower the recommended dose “because use of lower doses of Zolpidem will result in lower blood levels in the morning.”
The US Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) plans revisions to its Investigational Device Exemption process to improve clinical trial management for manufacturers and sponsors, and may also consider down-classifying some devices from Class III Premarket Approval registration requirements.
A wide variety of medical device stakeholders gave the Food and Drug Administration suggestions on how to improve the draft guidance for implementing the Global Unique Device Identification Database (GUDID).
Consultants for Booz Allen Hamilton recommend that the FDA implement more training, metrics and quality management to improve the consistency and transparency of the medtech review process.